Clinical trials: Pancreatic Metastasis
Unresectable Locally Advanced Cancer, Metastatic Pancreatic Cancer
Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer
Adapted Physical Activity (APA) program may provide an opportunity to improve symptoms for patients with unresectable pancreatic cancer.
- Trial name
- NCT02184663
- Testing
- without APA program, APA program
- Where
- 17 sites in France
- Volunteers
- 313 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreatic Neoplasms, Pancreatic Cancer
Project Survival-Prospective Biomarker Discovery
This sample-collection study is open to participants in several categories: healthy volunteers (with or without a family history of pancreatic cancer) and individuals diagnosed with pancreatitis or any stage of pancreatic cancer.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cancer, Pancreatitis, Pancreatic Adenocarcinoma
- Trial name
- NCT02781012
- Where
- 6 sites in United States
- Volunteers
- 436 people, healthy volunteers welcome
- Sponsor
- Pancreatic Cancer Research Team
Pancreatic Cancer
Perifosine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
RATIONALE: Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced…
- Trial name
- NCT00059982
- Testing
- perifosine
- Where
- 10 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Pancreatic Cancer, Adult
Adebrelimab and Chidamide for Pancreatic Cancer
Pancreatic cancer is a kind of digestive system tumor with high malignant degree and poor prognosis. Most patients with pancreatic cancer are locally advanced or have distant metastases at the time of diagnosis, so it is…
- Trial name
- ACPC (NCT06584227)
- Testing
- Adebrelimab and Chidamide Combined with Gemcitabine and S1
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Liu Xiufeng
Pancreatic Cancer
INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer
Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
- Trial name
- NCT00322712
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of New Mexico
Advanced Solid Tumor, Metastatic Solid Tumor
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Lung Cancer, Colorectal Cancer
- Trial name
- NCT05872867
- Testing
- WM-A1-3389, Pembrolizumab
- Where
- 2 sites in South Korea
- Volunteers
- 54 people
- Sponsor
- Wellmarker Bio
Metastatic Pancreatic Cancer
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
To investigate the tolerability and safety of ONO-7913 and ONO-4538 used in combination with modified FOLFIRINOX (mFFX therapy), the standard of care, as first-line treatment in patients with metastatic pancreatic cancer.
- Trial name
- NCT06532344
- Testing
- ONO-7913, ONO-4538, Oxaliplatin
- Where
- 9 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Pancreatic Cancer
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
This is a phase 2 clinical study,to explore the efficacy and safety of Disitamab Vedotin in patients with locally advanced or metastatic pancreatic cancer expressing HER2.
- Trial name
- NCT06233864
- Testing
- Disitamab Vedotin, Gemcitabine
- Volunteers
- 63 people
- Sponsor
- Sun Yat-sen University
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have…
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma
- Trial name
- NCT03368963
- Testing
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Emory University
Neuroendocrine Tumors
Capecitabine and Temozolomide for Neuroendocrine Cancers
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET).
- Trial name
- NCT00869050
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Columbia University
Metastatic Pancreatic Cancer
mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer
This phase Ⅱ study was designed to evaluate the efficacy and safety of mFOLFIRINOX as first-line treatment for metastatic pancreatic cancer in China.
- Trial name
- NCT02028806
- Testing
- mFOLFIRINOX
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Yuhong Li
Phase II, Open-label, Parallel 2-arm, Multi-center
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
Gemcitabine and nab-paclitaxel are one standard of care for metastatic pancreatic adenocarcinoma (mPDAC) but the progression free survival (PFS) of the regimen is only 5.5 months.
- Trial name
- NCT05026905
- Testing
- Gemcitabine 1000 mg, Nab paclitaxel, S1
- Where
- 4 sites in Taiwan
- Volunteers
- 66 people
- Sponsor
- National Health Research Institutes, Taiwan
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Cytomegalovirus Infections, Kidney Transplant Infection
Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients
This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients.
- Conditions
- Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant
- Trial name
- NCT06407232
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Wisconsin, Madison
Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
This randomized phase II trial studies how well selumetinib and Akt inhibitor MK2206 work compared to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) therapy in treating patients with metastatic pancreatic…
- Conditions
- Pancreatic Acinar Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer
- Trial name
- S1115 (NCT01658943)
- Testing
- Akt Inhibitor MK2206, Fluorouracil, Oxaliplatin
- Where
- 534 sites in United States
- Volunteers
- 137 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma
A Study of MLN0264 in Patients With Pancreatic Cancer
The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.
- Trial name
- NCT02202785
- Testing
- MLN0264
- Where
- 16 sites in United States, Belgium and 2 more
- Volunteers
- 43 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Pancreas Cancer, Pancreatic Cancer
Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood…
- Trial name
- Panc 002 (NCT06479239)
- Testing
- EGFR FPBMC
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Virginia
Extrahepatic Bile Duct Cancer, Pancreatic Cancer
Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00010088
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- 50 sites in France, Luxembourg
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Metastatic Pancreatic Cancer
Study to Evaluate the Safety, PK, and Efficacy of the Myc Inhibitor OMO-103 Administered iv in Patients With PDAC
This study is an open-label, multicentre, Phase 1b trial designed to determine the safety, tolerability, efficacy, PK, pharmacodynamics (PD) and proof-of-concept of OMO-103 in combination with the standard regimen…
- Trial name
- OMO-103-02 (NCT06059001)
- Testing
- OMO-103, Nab-Paclitaxel, Gemcitabine
- Where
- 6 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Peptomyc S.L.
Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT).
- Conditions
- Invasive Ductal Breast Carcinoma, Invasive Ductal Breast Carcinoma Stage IV, Lobular Breast Carcinoma, Lobular Breast Carcinoma Stage IV
- Trial name
- NCT05837767
- Testing
- Palliative radiotherapy
- Where
- 7 sites in United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.